Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aligos TherapeuticsALGS -8.93%37 3-Year EBITDA Growth Rate is 46.10% as of Mar. 2026, which is 2% above its 10-year median of 45.00. GuruFocus rates ALGS with a GF Score™ of 37/100 and a GF Value™ of $2.76 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,137 Biotechnology companies, Aligos Therapeutics ranks better than 82.67% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 46.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 47.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aligos Therapeutics was 48.00% per year. The lowest was 2.30% per year. And the median was 45.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Aligos Therapeutics 3-Year EBITDA Growth Rate Related Terms
ALGS vs SNTI, NTRB, CRVO: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Aligos Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aligos Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Aligos Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 46.10% mean?
Aligos Therapeutics (ALGS) has a 3-Year EBITDA Growth Rate of 46.10% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aligos Therapeutics and its competitors. This is near median its historical median of 45.00. Over the past decade, Aligos Therapeutics' 3-Year EBITDA Growth Rate has ranged from 2.30 to 48.00. According to the industry distribution chart, Aligos Therapeutics ranks #197 out of 1137 companies in the Biotechnology industry, placing it in the top 17.3%.
Is Aligos Therapeutics' 3-Year EBITDA Growth Rate too high?
Aligos Therapeutics' current 3-Year EBITDA Growth Rate of 46.10% is near median its 10-year median of 45.00. Over the past 10 years, this metric has ranged from a low of 2.30 to a high of 48.00. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Aligos Therapeutics' value of 46.10% is 209.4% above this industry median. Based on the distribution chart, Aligos Therapeutics ranks #197 out of 1137 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aligos Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' 3-Year EBITDA Growth Rate compare to SNTI and NTRB?
According to the Biotechnology industry distribution chart, Aligos Therapeutics ranks #197 out of 1137 companies for 3-Year EBITDA Growth Rate. This places Aligos Therapeutics in the top 17% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Aligos Therapeutics' value of 46.10% is 209.4% above this benchmark. Historically, Aligos Therapeutics' own 3-Year EBITDA Growth Rate has ranged from 2.30 to 48.00 over the past decade. While the company's 10-year median is 45.00 vs. the industry median of 14.90, Aligos Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,137 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aligos Therapeutics's current 3-Year EBITDA Growth Rate of 46.10% is 209.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aligos Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aligos Therapeutics's current 3-Year EBITDA Growth Rate is 46.10%, which is near median its own 10-year median of 45.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.76, compared to a current price of $4.67 — trading 69.2% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 46.10%, which is near median its 10-year median of 45.00 and 209.4% above the Biotechnology industry median of 14.90. Aligos Therapeutics' overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current 3-Year EBITDA Growth Rate is 46.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aligos Therapeutics (ALGS) Overvalued in 2026?
Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued.
The current stock price of $4.67 is trading 69.2% above its estimated GF Value™ of $2.76.
GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.
Key valuation signals for ALGS:
3-Year EBITDA Growth Rate: 46.10% (near median its 10-year median of 45.00)
GF Value™: $2.76 vs. price of $4.67 (69.2% above fair value)
Industry Position: 209.4% above the Biotechnology median (#197 of 1137)
No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
37GF Score
Get the complete analysis for ALGS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALGS has been successfully added to your 
